Q32 Bio Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Q32 Bio Inc. (QTTB) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $8.21 million as of 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2024-03-13
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.21M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.89M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.92M.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.37M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2023-12-31 | $8.21M 10-K · filed 2024-03-13 |
| 2022-12-31 | $7.89M 10-K · filed 2024-03-13 |
| 2021-12-31 | $6.92M 10-K · filed 2023-03-09 |
| 2020-12-31 | $1.37M 10-K · filed 2022-03-23 |
| 2019-12-31 | $883.00K 10-K · filed 2021-03-11 |
| 2018-12-31 | $443.00K 10-K · filed 2020-03-12 |
| 2017-12-31 | $27.00K 10-K · filed 2019-03-12 |